An end-to-end NLP pipeline that classifies text from three distinct domains into a 5-level sentiment scale (Very Negative to Very Positive). The project compares classical ML approaches (SVM, XGBoost) ...
The MarketWatch News Department was not involved in the creation of this content. HANGZHOU, China, March 10, 2026 /PRNewswire/ -- Westlake University today announced the launch of a free, open online ...
HANGZHOU, China, March 10, 2026 /PRNewswire/ -- Westlake University today announced the launch of a free, open online course on Natural Language Processing (NLP), taught by Professor Yue Zhang, head ...
Fiat Chrysler Automobiles in the US is settling a class action lawsuit tied to the 2015-2017 Chrysler 200, a midsize sedan that cannot seem to stay out of the paperwork. The dispute focuses on how ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
NEW YORK--(BUSINESS WIRE)--The RBB Fund Complex (“RBB”) proudly congratulates F/m Investments on the historic launch and trade of a multi-share class structure with both a mutual fund share class and ...
Lucas is a writer and narrative designer from Argentina with over 15 years of experience writing for games and news. He keeps a watchful eye at the gaming world and loves to write about the hottest ...
Drew Swanson is a Features Article Editor from the Pacific Northwest of the United States. Being a gamer all his life and enjoying everything from ARPGs like Diablo to JRPGs like Pokemon and Persona, ...
The term “min-maxer” in Dungeons and Dragons refers to someone who likes to push the TTRPG’s mechanics to their limits, optimizing a built character to have the strongest abilities imaginable. For any ...
Multifamily is facing a confluence of challenges—from the impact of tariffs and interest rates to rising construction and insurance costs. We asked apartment industry experts to zero in on these ...
BOULDER, Colo.--(BUSINESS WIRE)--Enveda, a multi-asset clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry ...